Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 253 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment... March 14, 2023 FDA Approves Liquid Biopsy NGS Companion Diagnostic Test for Multiple Cancers... November 10, 2020 Reunión anual de la American Society of Clinical Oncology de 2021:... June 3, 2021 Reducing Health Care Disparities Through Cancer Clinical Trials November 30, 2020 Load more HOT NEWS Some Women Avoid Breast Cancer Screening After False-Positive Mammogram Results How NatWest Group are making a difference this Giving Tuesday How Can Occupational Therapy Assist with Chemotherapy-induced Peripheral Neuropathy? Saying YES: Inspiring a Diverse Generation of Cancer Scientists
